Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

Introduction: EGFR tyrosine kinase inhibitor improved the survival of patients with metastatic EGFR mutation-positive (EGFRm+) NSCLC. Despite high response rates, resistance develops inevitably in every patient. In up to 13%, HER2 protein overexpression is found on progression. We hypothesized that...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	M. Jebbink, MD, A.J. de Langen, MD, PhD, K. Monkhorst, MD, PhD, M.C. Boelens, PhD, D. van den Broek, PhD, V. van der Noort, PhD, C.J. de Gooijer, MD, PhD, M. Mahn, MSc, A.J. van der Wekken, MD, PhD, L. Hendriks, MD, PhD, S.M.S. Hashemi, MD, PhD, M.S. Paats, MD, PhD, A.C. Dingemans, MD, PhD, E.F. Smit, MD, PhD
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2023-04-01
Цуврал:	JTO Clinical and Research Reports
Нөхцлүүд:	EGFR NSCLC Osimertinib Resistance HER2
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2666364323000206
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!